Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587844 · ClinicalTrials.gov registry record · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
A Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 8
- Study locations
NCT03587844 is a Phase 2 study of Mycosis Fungoides and Sezary Syndrome that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants, below the 161-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT03587844, a Phase 2 study of Mycosis Fungoides and Sezary Syndrome, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Conditions Studied
Interventions
- DRUG brentuximab vedotin
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03587844
The ClinicalTrials.gov registry entry for NCT03587844 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 161-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (64% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 1 intervention - of which brentuximab vedotin is the first listed.
NCT03587844 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT03587844 about?
NCT03587844 is a clinical study titled "Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients". The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
What is the current status of trial NCT03587844?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2018-07-03. Estimated completion is 2026-07.
What conditions does trial NCT03587844 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis.
What interventions are being tested in trial NCT03587844?
The interventions under investigation include: brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT03587844?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587844 being conducted?
This trial has 8 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
-
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.